Receipt of any investigational therapy is not permitted within 28 days prior to the first dose of nivolumab
Receipt of drugs with laxative properties and herbal or natural remedies for constipation within 90 days of receiving MEDI4736 or MEDI + tremelimumab
Receipt of any systemic anticancer therapy within 28 days prior to the first dose of MEDI5083
Receipt of any anticancer therapy within 4 weeks prior to the first dose of MEDI1873; in the case of mAbs, 6 weeks prior to the first dose of MEDI1873
Prior randomization or treatment in a previous MEDI4736 and/or tremelimumab clinical study regardless of treatment arm assignment or receipt of any investigational anticancer therapy within 28 days or 5 half-lives
Use of systemic steroids within 7 days before the first dose of MEDI-551 (inhaled and topical corticosteroids are permitted). Subjects may take replacement doses of steroids (defined as ? 30 mg/day hydrocortisone or the equivalent) if on a stable dose for at least 2 weeks prior to the first dose of MEDI-551. This does not include required steroid prophylaxis prior to the first infusion of MEDI-551
Receipt of any conventional or investigational anticancer therapy within 28 days prior to the first dose of MEDI0562.
Prior hormone therapy is allowed, but last dose must be at least 14 days prior to first dose of MEDI4276.
Receipt of any conventional or investigational anticancer treatment within 28 days prior to the first dose of MEDI4276.
Hemoglobin Â³ 9.0 g/dL within first 2 weeks prior to first dose of MEDI0680 (AMP-514)
Receipt of any BRAF inhibitor (in metastatic melanoma), or investigational anticancer therapy within 4 weeks prior to the first dose of MEDI0680 (AMP-514)
Receipt of any investigational anticancer therapy within 4 weeks prior to the first dose of MEDI0639 or in the case of monoclonal antibodies, 6 weeks prior to the first dose of MEDI0639
Receipt of any investigational anticancer therapy within 30 days prior to the first dose of MEDI3617, or in the case of monoclonal antibodies (eg, bevacizumab), 42 days prior to the first dose of MEDI3617
